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Transient receptor potential vanilloid I (TRPV1) sensitization in peripheral nociceptors
is a prominent phenomenon that occurs in inflammatory pain conditions. Pro-algesic
agents can potentiate TRPV1 activity in nociceptors through both stimulation of its
channel gating and mobilization of channels to the neuronal surface in a context
dependent manner. A recent study reported that ATP-induced TRPV1 sensitization
in peptidergic nociceptors involves the exocytotic release of channels trafficked by
large dense core vesicles (LDCVs) that cargo alpha-calcitonin gene related peptide
alpha (αCGRP). We hypothesized that, similar to ATP, bradykinin may also use
different mechanisms to sensitize TRPV1 channels in peptidergic and non-peptidergic
nociceptors. We found that bradykinin notably enhances the excitability of peptidergic
nociceptors, and sensitizes TRPV1, primarily through the bradykinin receptor 2 pathway.
Notably, bradykinin sensitization of TRPV1 in peptidergic nociceptors was significantly
blocked by inhibiting Ca2+-dependent neuronal exocytosis. In addition, silencing
αCGRP gene expression, but not substance P, drastically reduced bradykinin-induced
TRPV1 sensitization in peptidergic nociceptors. Taken together, these findings indicate
that bradykinin-induced sensitization of TRPV1 in peptidergic nociceptors is partially
mediated by the exocytotic mobilization of new channels trafficked by αCGRP-
loaded LDCVs to the neuronal membrane. Our findings further imply a central role
of αCGRP peptidergic nociceptors in peripheral algesic sensitization, and substantiate
that inhibition of LDCVs exocytosis is a valuable therapeutic strategy to treat pain, as
it concurrently reduces the release of pro-inflammatory peptides and the membrane
recruitment of thermoTRP channels.
Keywords: nociceptors, TRPV1, inflammation, neuropeptides, exocytosis
INTRODUCTION
Transient receptor potential vanilloid I (TRPV1) is a non-selective cation channel that can
be activated by noxious heat (T ≥ 42◦), vanilloids, protons, voltage, toxins, and membrane
derived lipids (Caterina et al., 1997; Zygmunt et al., 1999; Huang et al., 2002; Chu et al., 2003).
Physiologically, TRPV1 acts as a major integrator of painful stimuli in nociceptors. During
Abbreviations: AP, action potential; BK, bradykinin; αCGRP, α calcitonin gene-related peptide; cps, capsaicin; IB4, isolectin
B4; LDCV, large-dense core vesicle; MEA, multielectrode array; RMP, resting membrane potential; SP, substance P; Tac,
tachykinin; TRPV1, transient receptor potential vanilloid I.
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inflammation, the release of inflammatory mediators potentiate
TRPV1 activity leading to enhanced nociceptor excitability
that results in thermal hyperalgesia (Planells-Cases et al.,
2005; Huang et al., 2006; Siemens et al., 2006; Yu et al.,
2008). In rats, TRPV1 is widely expressed in both medium
size Aδ-fibers and small size C-fibers including peptidergic
and non-peptidergic subpopulations (Mitchell et al., 2010).
At variance with rats, the expression of TRPV1 is primarily
restricted to the peptidergic subpopulation in adult mice
(Cavanaugh et al., 2011). Cumulative evidence indicates that
acute inflammatory sensitization of TRPV1 involves both the
modification of channel gating properties by phosphorylation
(Srinivasan et al., 2008) and the recruitment of channels to
the neuronal surface (Morenilla-Palao et al., 2004). Mobilization
of new channels to the plasma membrane induced by some
pro-inflammatory mediators occurs through SNARE-dependent
exocytosis (Camprubí-Robles et al., 2009), but the exact
mechanism involved remains under investigation. A recent
study showed that ATP-induced inflammatory recruitment of
TRPV1 channels occurs specifically in peptidergic nociceptors
by Ca2+-dependent exocytosis of large dense core vesicles
(LDCVs; Devesa et al., 2014). Furthermore, evaluation of the
cellular mechanism revealed that the neuropeptide αCGRP
was essential for the inflammatory recruitment of TRPV1
channels in peptidergic nociceptors. This finding suggests
that a similar mechanism may underlie the potentiation
of TRPV1 by other pro-inflammatory agents. In support
of this tenet, inhibition of TRPV1 recruitment by peptide
DD04107, a blocker of neuronal exocytosis (Camprubí-Robles
et al., 2009), exhibits notable anti-nociceptive activity in
models of inflammatory and neuropathic pain (Ponsati et al.,
2012).
Bradykinin (BK) is a potent algogenic non-apeptide released
from mast cells and basophils during tissue damage (Dray
and Perkins, 1993; Raidoo and Bhoola, 1998; Cesare et al.,
1999). BK exerts its inflammatory action through BKR1 and
BKR2 metabotropic receptors, which trigger second messenger
signaling through Gαq proteins (Mizumura et al., 2009). BKR2
receptor expression is ubiquitous and constitutive, whereas,
BKR1 receptor is expressed under chronic inflammatory
conditions. It has been documented that BK can sensitize
TRPV1 through PKC and PKA-mediated phosphorylation of
specific intracellular Ser/Thr sites in the receptor, leading to
enhanced activity (Cesare and McNaughton, 1996; Stucky and
Lewin, 1999; Premkumar and Ahern, 2000; Sugiura et al.,
2002; Zhang et al., 2008; Wang et al., 2015), and that this
sensitization may not involve recruitment of new channels to
the plasma membrane (Camprubí-Robles et al., 2009). However,
numerous in vitro studies on primary cultures of nociceptors
have reported a possible BK-induced stimulation of neuronal
trafficking of receptors to the cell surface. In this regard, BK-
induced trafficking of opioid receptors in nociceptors has been
studied (Patwardhan et al., 2005; Pettinger et al., 2013). Likewise,
BK has also been involved in the Ca2+-dependent exocytotic
release of αCGRP in primary sensory neurons (Meng et al.,
2007; Supowit et al., 2011), as BK releases Ca2+ from the
endoplasmic reticulum. These evidences suggest that BK may
also potentiate TRPV1 activity in nociceptors by promoting its
membrane mobilization in peptidergic nociceptors akin to ATP
(Devesa et al., 2014).
Here, we investigated this hypothesis and studied the
mechanism of BK-induced inflammatory sensitization of TRPV1
in cultured peptidergic and non-peptidergic nociceptors.
We found that inhibition of neuronal exocytosis with
DD04107 resulted in a decreased BK-induced sensitization
of TRPV1 in peptidergic nociceptors but not in non-
peptidergic sensory neurons. In addition, knocking out
αCGRP expression, but not substance P, markedly reduced
BK-evoked potentiation of TRPV1 in peptidergic nociceptors.
Hence, our findings substantiate an essential role of neuronal
exocytosis of LDCVs containing αCGRP in the potentiation
of TRPV1 by pro-algesic agents in peptidergic C-type
nociceptors.
MATERIALS AND METHODS
Chemicals
DD04107 (Palmitoyl-EEQMRR-NH2), DD04107RDM (Palmitoyl-
EQREMR-NH2) and non-palmitoylated DD04107 (Ac-
EEQMRR-NH2) were kindly provided by BCN Peptides,
Barcelona, and freshly prepared at 20 mM in H2O. For
microelectrode array, cells were incubated with 20 µM DD04107
in HBSS for 1 h (37◦C, 5% CO2). For electrophysiological
recordings, non-palmitoylated DD04107 was prepared at
100 µM in standard internal solution from 10 mM stock
solution in H2O. Peptide or vehicle were applied through the
patch pipette 10 min before recording. Capsaicin was dissolved
in DMSO at 10 mM and further diluted in HBSS at 500 nM
for MEAs and 1 µM for patch clamp experiments. BK was
dissolved in H2O at 1 mM and further diluted in HBSS at
1 µM. The BKR1 agonist Sar-[D-Phe8]-des-Arg9-BK and the
BKR2 agonist [Phe8ψ(CH-NH)-Arg9]-BK (Tocris Bioscience,
R&D Systems) were dissolved in H2O at 1 mM and further
diluted in HBSS at 1 µM. The BKR1 antagonist R715 and the
BKR2 antagonist HOE140 (Tocris Bioscience, R&D Systems)
were dissolved in H2O at 1 mM and further diluted in HBSS
at 1 µM. Unless indicated, all chemicals were obtained from
Sigma-Aldrich.
Animals
All procedures were approved by the Institutional Animal
and Ethical Committee of the University Miguel Hernández
de Elche, in accordance with the guidelines of the Economic
European Community, the National Institutes of Health,
and the Committee for Research and Ethical Issues of the
International Association for the Study of Pain. Animals
were kept in a controlled environment (21–23◦C, 12 h
light/dark cycle), and had food and water available ad libitum.
Neonatal Wistar rats and wild type C57BL/6J mice were
purchased from in house bred stock (originally from Harlan
Laboratories). Tac1-deficient mice (B6.Cg-Tac1tm1Bbm/J)
that do not express Substance P were purchased from
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The Jackson Laboratory. α-CGRP-deficient mice (B6;129-
CalcaTM) were produced as described (Salmon et al.,
1999).
Primary Culture of Sensory Neurons
DRG from neonatal Wistar rats (3–5 days-old) or adult male 12–
15 weeks-aged mice (strains: C57BL/6J, αCGRP−/−, Tac1−/−),
were cultured following previously described protocols with
some modification (Baker and Bostock, 1997; Bonnington and
McNaughton, 2003; Devesa et al., 2014). Briefly, neonatal rat
ganglia were digested with 0.25% (w/v) collagenase (type IA) in
DMEM-glutamax (Invitrogen) with 1% penicillin-streptomycin
(P/S; 5000 U/mL, Invitrogen) for 1 h (37◦C, 5% CO2). Isolated
mouse DRG were incubated with 0.67% (w/v) collagenase type
XI and 3% (w/v) dispase (Gibco) in INC mix medium (in mM):
155 NaCl, 1.5 K2HPO4, 5.6 HEPES, 4.8 NaHEPES, 5 glucose)
for 1 h (37◦C, 5% CO2). After digestion, rat and mouse DRGs
were mechanically dissociated using a glass Pasteur pipette. Single
cell suspension was passed through a 100 µm cell strainer, and
washed with DMEM glutamax plus 10% fetal bovine serum (FBS;
Invitrogen) and 1% penicillin/streptomycin. Cells were seeded at
the required density for each experiment on 12 mm cover-glass
slides, or microelectrode array chambers previously coated with
poly-L-lysine (8.3 µg/mL) and laminin (5 µg/mL). After 2 h,
medium was replaced with DMEM glutamax, 10% FBS and 1%
P/S, supplemented with mouse 2.5S NGF 50 ng/mL (Promega)
and 1.25 µg/mL cytosine arabinoside when required (37◦C, 5%
CO2). Unless otherwise indicated, all experiments were made
48 h after cell seeding.
Patch-Clamp Recordings
Whole-cell voltage clamp was made in neurons seeded on
coverslips, placed in RC-25 chamber and connected to a external
perfusion system at ≈22◦C. External solution was (in mM):
140 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 5 D-glucose,
20 mannitol, pH 7.4 (adjusted with NaOH). Internal pipette
solution was (in mM): 144 KCl, 2 MgCl2, 10 HEPES, 5 EGTA,
pH 7.2 (adjusted with KOH). Membrane currents were acquired
using EPC10 HEKA Patch amplifier (HEKA Electronics). Cells
were held at a RMP of −60 mV, and at a sampling rate of
2.5 Hz. Patch glass pipettes with OD 1.5 mm × I.D. 1.17 mm
(Harvard Instruments) were pulled with a Sutter Pippete puller
Equipment (Sutter Instruments) to have a 3–6 M resistance.
Data acquisition and oﬄine analysis were performed with
PatchMaster software (HEKA Electronics). Rat DRG neurons
were labeled with IB4-alexa 568 (10 µg/mL, 10 min, RT) in the
external solution (Molecular Probes, Invitrogen), followed by two
5 min-washes. Labeled neurons were visualized through x20 air
objective (Axiovert 200 inverted microscope, Carl Zeiss), with an
excitation filter ET545 and an emision filter ET605 (CHR-49004,
Laser 2000 SAD). Neuronal viabiliy was determined through
typical neuronal Na+–K+ currents. TRPV1 desensitization was
evoked by three repetitive 10 s-pulse of 1 µM capsaicin using a
gravity-driven perfusion system (2 mL/min; Devesa et al., 2014).
BK (1 µM) was applied for 8 min between P2 and P3 capsaicin
pulses. Potentiation of TRPV1-mediated currents was calculated
as the ratio of P3/P2 current peaks.
Electrical Properties
Electrical properties of the neuron were determined 2 min
after establishing whole cell access using the current-clamp
mode. For current-clamp recording, cells were held at 0 pA.
Cells were assessed for the presence of spontaneous activity
for 1 min and processed to measure electrogenic properties.
Both IB4− and IB4+ nociceptors were processed for electrogenic
properties before BK application. Firing threshold was measured
first by injecting a series of 100 ms depolarising current in
10 pA steps from 0 pA to elicit the first AP. To examine
the neurons firing properties, a depolarising current of 40 pA
(IB4−) and 100 pA (IB4+) of 100 ms was injected to fire
APs. APs were analyzed for the following intrinsic membrane
properties: threshold potential (mV), amplitude of AP (mV),
duration of AP (ms), overshoot of AP (mV), amplitude of
afterhyperpolarization potential (mV). BK (1 µM) was applied
to IB4− and IB4+ nociceptors for 4 min to observe BK induced
spontaneous neuronal excitabilities. RMP was checked before
and after BK application. Mean depolarization was calculated by
selecting the maximum depolarized voltage observed upon BK
application in IB4− and IB4+ nociceptors. Nociceptors (IB4−
and IB4+) were injected with 100 pA for 100 ms and 300 pA
for 1 s to measure electrically evoked APs. BK induced changes
in electrically evoked APs were measured before and after BK
application.
MEA Measurements
Extracellular recordings were made using multiple electrode
planar arrays of 60-electrode thin MEA chips, with 30 µm
diameter electrodes and 200 µm inter-electrode spacing with an
integrated reference electrode (Multichannel Systems GmbH).
The electrical activity of primary sensory neurons was recorded
by the MEA1060 System (Multi Channel Systems GmbH1),
and MC_Rack software version 4.3.0 at a sampling rate of
25 kHz. TRPV1-mediated neuronal firing activity was evoked
by three repetitive 15 s-applications of 500 nM capsaicin, using
continuous perfusion system (2 mL/min). BK (1 µM) in external
solution was perfused between P2 and P3 for 8 min. For
experiments on BK receptor agonists, selective BK receptor
agonists for BKR1 and BKR2 were applied between P2 and
P3 for 8 min. Data were analyzed using MC_RACK spike
sorter and Neuroexplorer Software (Nex Technologies). An
evoked spike was defined when the amplitude of the neuronal
electrical activity overcame a threshold set at −20 µV. The
recorded signals were then processed to extract mean spike
frequency.
Data Analysis
All data are expressed as mean ± SEM, with n as number of
registered cells and N as the number of independent experiments.
The percentage of sensitized neurons was calculated considering
those cells that exhibited a fold potentiation (P3/P2) above 1.1.
Statistical analysis was made using the Wilcoxon Rank test or
Student’s t-test (unpaired or paired), one-way ANOVA or two-
way ANOVA followed by Bonferroni’s post hoc test as indicated
1http://www.multichannelsystems.com
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using the GraphPad Prism 5.0 (Graph-Pad). MEA data were
analyzed by Bonferroni’s post hoc test as paired values through
comparison of the responses of each electrode in the 30-s
time interval upon stimulation. p < 0.05 was considered to be
significant for a difference.
RESULTS
BK Modulates Electrogenic Properties of
Peptidergic and Non-peptidergic
Nociceptors
As a preliminary step, we characterized the effect of BK on the
electrical properties of peptidergic (IB4−) and non-peptidergic
(IB4+) nociceptors. For this purpose, BK-induced changes in
spontaneous neuronal activity, RMP and the properties of
electrically evoked APs were investigated in primary cultures
of neonatal rat nociceptors. For these experiments, IB4+
nociceptors were fluorescently labeled with Alexa-IB4, and
nociceptor excitability was evaluated by whole cell patch-clamp.
First, neurons were recorded for their RMP for 1 min after
seal formation. Thereafter, these nociceptors were perfused with
1 µM BK for 4 min and an electrical response typically began
within a minute of the pro-inflammatory agent application
(Figure 1A). As seen, exposure of IB4− nociceptors to BK
produced a depolarization of the RMP that resulted in the
firing of APs. In marked contrast, exposure of IB4+ neurons
to BK did not result in a significant alteration of the RMP
nor firing of APs. Quantification of the mean RMP reveals a
more depolarized value for IB4− nociceptors (−45 ± 2 mV)
than for IB4+ neurons (−56 ± 1 mV; Figure 1B). Furthermore,
despite of the variability inherent in primary nociceptor cultures,
BK produced a significant depolarization in the mean RMP
value (≈7 mV) of IB4− nociceptors, indicating a direct effect
of the pro-algesic agent in the excitability of peptidergic
nociceptors.
Increase in nociceptor excitability or sensitization by
inflammatory mediators has been associated with lower
threshold requirement to fire APs and to an increased firing
frequency in response to depolarizing stimuli (Gold and Traub,
2004). Next, we investigated the impact of BK exposure on
electrically evoked APs in nociceptors. First, nociceptors (IB4−
and IB4+) were examined for evoked excitability in basal
conditions upon injecting a depolarizing current pulse of
100 pA for 100 ms or of 300 pA for 1 s (Figure 2, vehicle).
In both conditions, IB4− nociceptors displayed significantly
higher electrically evoked activity than IB4+ neurons. Second,
1 µM BK was applied for 4 min and nociceptors were retested
for changes in evoked APs. Exposure of IB4− nociceptors
to BK depolarized the RMP, and increased the frequency of
electrically activated APs by ≥1.5-fold, as evidenced for the
two current injections (Figures 2A,C). Similarly, exposure
of IB4+ nociceptors to BK also resulted in an increment in
the electrically evoked AP firing, especially when 300 pA
were applied (Figures 2B,D). Collectively, these findings
indicate that peptidergic nociceptors are more excitatable and
more reactive to acute BK sensitization than non-peptidergic
nociceptors.
BK-Induced Sensitization of TRPV1 in
Nociceptors is Mainly Mediated by BK2R
Receptors
We next investigated the potentiating effect of BK on TRPV1
channels. For these experiments, we used the MEA technology
to monitor the electrical activity of primary cultures of rat
DRG neurons evoked by capsaicin. To register neuronal activity,
a continuous protocol was used where two 15 s pulses of
500 nM capsaicin interspersed by a washing period of 3 min
FIGURE 1 | Effect of BK on modulating excitability of neonatal rat peptidergic IB4− and non-peptidergic IB4+ neurons. (A) Representative of the RMP
change in a peptidergic (red) and a non-peptidergic (blue) neuron upon exposure to 1 µM BK. (B) Effect of BK on the RMP in from peptidergic and non-peptidergic
neuron before and after 1 µM BK application. Each point represents a neuron from three independent cultures. Statistical analysis was performed using the
non-parametric Wilconson Rank sum test.
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FIGURE 2 | Effect of BK on evoked responses of IB4− and IB4+ soma to depolarizing currents. Representative traces of APs evoked by injecting a
depolarizing current of 100 pA (100 ms) and 300 pA (1 s) delivered to the soma of IB4− (A,C) and IB4+ (B,D) neurons before (Vehicle) and after instillation to
1 µM BK.
FIGURE 3 | Sensitization of TRPV1 activity by BK, BKR1 and BKR2 receptor agonists. (A,B) Representative traces of capsaicin (cps = 500 nM, 15 s) evoked
APs in neonatal rat DRG neurons upon applying buffer (Control) or 1 µM of BK between the second (P2) and third (P3) vanilloid pulse, respectively.
(C) Representative recordings of 1 µM Sar-[D- Phe8]-des-Arg9-Bradykinin (BKR1), and (D) 1 µM BKR2 ([Phe8ψ(CH-NH)-Arg9]-Bradykinin; BKR2) inducing
potentiation of capsaicin evoked neuronal excitability in rat nociceptors. (E) BK receptor agonists evoked fold potentiation (ratio P3/P2) of TRPV1 mediated neuronal
firing activity. (F) BK evoked fold potentiation (ratio P3/P2) of TRPV1 mediated neuronal firing activity in the presence of BK receptor antagonists (1 µM R715 for
BKR1, 1 µM HOE140 for BKR2). Data were analyzed as paired values through comparison of the responses of each electrode in the 30 s time interval upon
stimulation. Data are expressed as mean ± SEM. The numbers above the bars represents the total number of electrodes that responded. Number of cultures ≥3.
Statistical analysis was performed by one-way ANOVA followed by Bonferroni post hoc test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
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were applied, followed by an 8-min incubation with vehicle
or 1 µM BK, and finalized by a third (P3) capsaicin pulse
(Figures 3A,B). As seen, successive capsaicin pulses led to
TRPV1 tachyphylaxia as evidenced by the lower AP firing
evoked by the second (P2) and third (P3) pulses (Figure 3A).
Application of BK after the second capsaicin pulse resulted
in an increment of neuronal activity directly evoked by BK
(Figure 3B). Notably, a subsequent capsaicin pulse (P3) produced
a significant augment of the vanilloid response as compared
with the second pulse (Figure 3B), consistent with a BK-induced
potentiation of TRPV1 responses. Analysis of the mean spike
frequency of each capsaicin pulse and the fold potentiation
(estimated as the ratio P3/P2) substantiates this finding, revealing
that BK increased the TRPV1 activity by 2.6 ± 0.4 fold
(Figure 3E).
It has been documented that BK induces nociceptor
potentiation mainly through BKR2 receptors, which are
expressed constitutively in peptidergic nociceptors (Seabrook
et al., 1997; Lee et al., 2002). In contrast, BKR1 receptors
expression appears to be induced during inflammation in
IB4+ non-peptidergic nociceptors (Davis and Perkins, 1994;
Vellani et al., 2004; Petho and Reeh, 2012), with limited studies
reporting a constitutive expression of BK1R receptors in
nociceptors (Wotherspoon and Winter, 2000; Ma, 2001). Thus,
the question that raises is which receptor isoform is mediating
BK-induced TRPV1 sensitization in nociceptors. To explore
the contribution of BKR1 and BKR2 receptors on BK induced
TRPV1 sensitization, the BKR1 agonist Sar-[D-Phe8]-des-Arg9-
BK) and the BKR2 agonist ([Phe8ψ(CH-NH)-Arg9]-BK) were
used in an identical experimental paradigm as above. Figure 3C
illustrates that BKR1 agonist modestly evoked neuronal firing
and marginally promoted TRPV1-mediated neuronal spikes.
In marked contrast and akin to BK, the BKR2 agonist notably
increased nociceptor firing and strongly potentiated TRPV1
induced neuronal spiking (Figure 3D). Quantification of the
mean spike frequency further substantiates the prominent
effect of the BKR2 ligand as compared with that of BKR1.
Notably, the fold potentiation of TRPV1-evoked neuronal
spikes induced by BKR2 ligands (2.9 ± 0.3) is virtually identical
to that evolved by BK (2.6 ± 0.4; Figure 3E) implying that
BK exerts mainly its action through BKR2. In support of this
tenet, no significant increase in the fold potentiation of TRPV1
evoked neuronal spikes was observed in neurons treated with
the BKR1 agonist (Figure 3C). These results were further
corroborated by using specific blockers of both receptor subtypes
(Figure 3F). Collectively, these findings suggest that BK induces
sensitization of TRPV1 mainly through activation of BKR2 in
nociceptors.
BK Sensitized, TRPV1-Mediated
Neuronal Firing of Nociceptors is
Blocked by DD04107
Recent studies revealed that acute incubation of IB4− nociceptors
with BK induced the release of αCGRP in a dose-dependent
manner through activation of the Gαq/11 signaling pathway
(Supowit et al., 2011). Our earlier findings showed that the
algogen ATP, that also activates the Gq/11 signaling pathway,
sensitizes TRPV1 in peptidergic nociceptors promoting the
exocytosis of LDCVs carrying the receptor (Devesa et al., 2014).
Henceforth, we hypothesized that BK may also induce TRPV1
sensitization through the exocytotic recruitment of new TRPV1
channels present in LDCVs.
To investigate if BK promotes the membrane mobilization
of TRPV1 we evaluated the impact of inhibiting neuronal
exocytosis of LDCVs using compound DD04107, a small
lipidated peptide that interferes with the formation of the
SNARE complex (Camprubí-Robles et al., 2009). For these
experiments, we also used the MEA technology to monitor
the electrical activity of primary cultures of rat DRG neurons
(Devesa et al., 2014) utilizing an identical experimental protocol
as above. In control cultures, two successive capsaicin pulses
led to TRPV1 tachyphylaxia as evidenced by the lower AP
firing evoked by the second (P2) pulse (Figure 4A). Application
of BK after the second capsaicin pulse to cultures exposed to
vehicle resulted in an increment of neuronal activity directly
evoked by the kinin (Figure 4A, vehicle). A subsequent
capsaicin pulse (P3) produced a significant augment of the
vanilloid response as compared with the second pulse, consistent
with a BK-induced potentiation of TRPV1 responses. Analysis
of the mean spike frequency of each capsaicin pulse and
the fold potentiation of these experiments (estimated as the
ratio P3/P2) substantiates this finding, revealing that BK
increased the TRPV1 activity in nociceptors by ≥2.0 fold
(Figures 4B–D).
We next evaluated the effect of peptide DD04107 on the
BK potentiation of capsaicin responses. For these experiments,
primary cultures of rat nociceptors were pre-incubated with
20 µM DD04107 for 1 h. As a control, we used 20 µM
compound DD04107RDM, a peptide with the same amino acid
composition but random sequence. Neither peptide affected the
capsaicin nor BK responses as illustrated in Figure 4A (DD04107
and DD04107RDM). As for control conditions, two consecutive
pulses of the vanilloid-induced TRPV1 tachyphylaxia. Notably,
exposure of nociceptors to 1µM BK did resulted in a significantly
lower potentiation of the response to the third capsaicin pulse
in nociceptors incubated with peptide DD04107 as compared
with those incubated with vehicle or DD04107RDM. This is
clearly discerned in the mean spike frequency and in the
fold potentiation (Figures 4B–D). As illustrated in Figure 4,
DD04107 notably inhibited the fold potentiation of vanilloid
responses evoked by BK (Figure 4C). In contrast, DD04107RDM
did not affect the sensitizing effect of the kinin (Figure 4D).
Though we observe a lower potentiation of TRPV1 activity
by BK in DD04107-exposed neurons compared to vehicle and
DD04107RDM-treated nociceptors, we still notice potentiation of
TRPV1 evoked excitability upon inhibiting neuronal exocytosis
with DD04107 (Figures 4A,B). This result is consistent with the
tenet that other mechanisms, apart from channel recruitment
to the cell surface, are involved in BK-induced TRPV1
sensitization. Taken together, our findings imply that TRPV1
sensitization by BK in nociceptors is partially mediated by the
exocytotic recruitment of new TRPV1 channels to the neuronal
surface.
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FIGURE 4 | Peptide DD04107 inhibits BK-sensitized TRPV1-mediated nociceptor excitability. (A) Representative traces of capsaicin-evoked APs upon
applying BK between the second (P2) and third (P3) vanilloid pulses in neonatal rat DRG neurons exposed to vehicle, DD04107 and DD04107RDM peptides.
(B) Mean spike frequency of capsaicin evoked AP firing under control (buffer) and BK-treated conditions in the presence of vehicle and peptides DD04107 and
DD04107RDM. (C,D) Fold potentiation (ratio P3/P2) of BK-induced potentiation of TRPV1 evoked neuronal firing in the presence of peptide DD04107 and
DD04107RDM respectively. Capsaicin (cps = 500 nM, 15 s) and BK (1 µM, 8 min) were used. DD04107 and DD04107RDM (20 µM) were pre-incubated for 1 h at
37◦C. Mean spike frequency was calculated from recordings displayed in (A). Data were analyzed as paired values through comparison of the responses of each
electrode in the 30 s time interval upon stimulation. Data are expressed as mean ± SEM. The numbers above the bars represents the total number of electrodes that
responded. Number of independent cultures ≥3. Statistical analysis was performed by one-way ANOVA repeated measures with Bonferroni’s post hoc test and
Unpaired Student’s t-test (∗p < 0.05, ∗∗p < 0.01).
FIGURE 5 | Effect of non-palmitoylated DD04107 on BK-induced sensitization of TRPV1 channel on rat peptidergic and non-peptidergic DRG
neurons. (A,B) Representative showing the effect of 1 µM BK on the ionic currents elicited by capsaicin (cps = 1 µM, 10 s) in IB4− and IB4+ nociceptors,
respectively. (C,D) Effect of 100 µM non-palmitoylated DD04107 peptide (denoted as Peptide) on the BK-induced potentiation of capsaicin-evoked ionic currents in
IB4− and IB4+ nociceptors, respectively. (E) Fold potentiation (ratio P3/P2) of capsaicin-evoked ionic currents by BK in cultures exposed to vehicle and peptide.
Cells were held at −60 mV. Peptide was given through the patch pipette and incubated for 10 min after forming the seal. Data are expressed as mean ± SEM. The
numbers above the bars denote the total neurons registered. Number of independent cultures = 4. Statistical analysis was performed using two-way ANOVA with
Bonferroni’s post-test (∗p < 0.05, ∗∗p < 0.01).
BK Sensitization of TRPV1 in Peptidergic
Nociceptors is Sensitive to Blockade of
Neuronal Exocytosis
From our previous results, a question that emerges is whether
BK-induced exocytotic mobilization of TRPV1 channels to the
plasma membrane is a mechanism used by both types of
nociceptors or by a specific subtype. Thus, we next examined the
effect of peptide DD04107 on BK-induced TRPV1 sensitization
in IB4− and IB4+ nociceptors. For these experiments, IB4+
nociceptors were fluorescently labeled with Alexa-IB4, and
TRPV1 channel activity was evaluated by whole cell patch-clamp.
Figure 5A shows that capsaicin-induced TRPV1 desensitization
in IB4− nociceptors was strongly potentiated by 1 µM BK.
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Notably, BK-promoted TRPV1 sensitization in IB4− sensory
neurons was virtually abolished by 100 µM of the non-
palmitoylated DD04107 peptide derivative delivered to the
neuronal cytosol through the patch pipette. These results are
corroborated upon calculating the fold potentiation of TRPV1
currents by taking the ratio of P3 and P2 (P3/P2; Figure 5E). No
significant change in the fold potentiation was observed under
control conditions for vehicle and peptide groups. However,
the TRPV1 activity was ≈1.7-fold higher after BK incubation
compared to control (Figure 5E). Noteworthy, the BK-induced
increase in TRPV1 potentiation in IB4− was fully blocked by the
non-palmitoylated peptide DD04107 (Figures 5C,E), consistent
with the tenet that BK sensitizes TRPV1 by promoting its
mobilization to the neuronal surface.
At variance with IB4− nociceptors, BK did not induce
significant TRPV1 sensitization in IB4+ sensory neurons
(Figure 5B). Consistent with the current recordings, there was no
fold potentiation of TRPV1 evoked by BK in IB4+ nociceptors
(Figure 5E) and, consequently, there was no effect of the non-
palmitoylated DD04107 peptide (Figures 5D,E). Collectively,
these results suggest that most of the TRPV1 sensitizing action
produced by BK occurs in peptidergic nociceptors with a
marginal contribution of the IB4+, non-peptidergic population.
This is consistent with the finding that BK signals mainly through
BKR2.
Silencing of α-CGRP Abrogates BK
Induced Sensitization of TRPV1
In a previous study, we reported that ATP-evoked TRPV1
potentiation in IB4− peptidergic nociceptors was strictly
dependent on the expression of αCGRP in these nociceptors
(Devesa et al., 2014). Genetic ablation of αCGRP expression
in mice fully abolished inflammatory recruitment of TRPV1
to the neuronal surface. Thus, we next evaluated whether BK-
evoked TRPV1 sensitization also required the expression of
pro-inflammatory peptides, αCGRP and/or SP, in peptidergic
nociceptors. To address this question, we used DRG nociceptors
from αCGRP and SP null mice, and monitored the electrical
activity evoked with capsaicin using the MEA technology. We
first examined the effect of BK sensitizing TRPV1 activity in
mice nociceptors in culture. As illustrated in Figure 6A, BK
potentiated capsaicin responses in mice nociceptors in a slightly
lower extend than their counterpart from rat (Figures 3B
and 6A). This is clearly discerned in the mean spike frequency
(Figures 3E and 6C). Notice that BK also produced less spikes
in mice nociceptors than in rat nociceptors. Furthermore,
BK-evoked TRPV1-sensitization was highly sensitive to the
inhibitory action of DD04107 (Figures 6B,C), indicating a similar
sensitizing mechanism to that reported for rat nociceptors,
namely recruitment of new channels to the neuronal surface.
Next, we performed the same measurements in nociceptors
from αCGRP (αCGRP−/−, Figure 7) and SP (Tac−/−, Figure 8)
null mice. In sensory neurons from αCGRP−/− mice, BK
was unable to potentiate TRPV1-evoked neuronal excitability
(Figures 7A,B), similar to the blockade exerted with DD04107. In
contrast, BK evoked strong TRPV1 sensitization in nociceptors
from Tac−/− mice (Figure 8). These results clearly imply
that, akin to ATP, BK-promoted TRPV1 sensitization in IB4−
peptidergic nociceptors was dependent on the expression of
αCGRP, and further imply that a population of TRPV1
is trafficked to the neuronal terminals in LDCVs loaded
with αCGRP. Thus, pro-inflammatory mediators sensitize
nociceptors by the concomitant release of αCGRP and the
membrane recruitment of TRPV1 channels. This finding further
corroborates that inflammatory sensitization of TRPV1 in
peptidergic nociceptors involves the exocytotic delivery of new
channels trafficked by LDCVs to the neuronal surface.
DISCUSSION
Algesic sensitization of nociceptor peripheral terminals leading to
enhanced excitability is a major component of pain transduction.
In physiological conditions, peripheral nociceptor terminals are
very silent, and only activated when a noxious stimulus is
perceived, therefore acting as a protective mechanism to preserve
tissue integrity. In contrast, upon tissue damage or inflammation,
a plethora of algogen factors are released from damaged
nociceptors and surrounding immune cells that act on nociceptor
receptors, primarily augmenting nociceptor excitability (Gold
and Traub, 2004), i.e., an increase in the firing of APs that leads
to pain (Mamet et al., 2002). A pivotal action of released algogens
is the potentiation of TRPV1 channel activity, an AP generator in
nociceptors, by favoring its gating and augmenting its membrane
expression (Morenilla-Palao et al., 2004; Srinivasan et al., 2008;
Camprubí-Robles et al., 2009). We previously reported that
membrane mobilization of TRPV1 channels to the neuronal
surface by pro-algesic agents is a mechanism involved in the
in vitro and in vivo sensitization of nociceptors as its blockade
by compound DD04107, an inhibitor of neuronal exocytosis,
attenuates receptor sensitization and results in antinociception
(Camprubí-Robles et al., 2009; Ponsati et al., 2012). Similarly,
Botulinum neurotoxin A is also an effective anti-nociceptive drug
widely used to treat several painful human syndromes (Cui et al.,
2004; Shimizu et al., 2012; Kim et al., 2015; Sidaway, 2015),
implying that algesic mobilization of TRPV1 may be a general
mechanism for nociceptor sensitization. However, we found
that ATP-induced TRPV1 sensitization involved membrane
mobilization of new channels only in peptidergic nociceptors
(Devesa et al., 2014). These findings imply that inflammation-
induced surface recruitment of TRPV1 may be a sensitizing
mechanism used by peptidergic nociceptors that cargo TRPV1 in
αCGRP-loaded LDCVs.
We have further tested this hypothesis and investigated
the molecular sensitizing mechanism of BK, a kinin that
acts as a strong pro-algesic agent (Walker et al., 1995). The
salient contributions of this study are that: (i) BK directly
triggers electrical activity and strongly sensitizes peptidergic
nociceptors, while exhibits a moderate effect on non-peptidergic
neurons; (ii) acute BK nociceptor sensitization is mainly through
BKR2, which are highly expressed in peptidergic nociceptors.
(iii) BK potentiates TRPV1 activity in peptidergic nociceptors
by a mechanism that partially involves the mobilization of
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FIGURE 6 | BK-induced potentiation of TRPV1 evoked neuronal firing in mice nociceptors is sensitive to DD04107. (A) Representative MEA recordings of
capsaicin induced action potentials (APs) and desensitization (Top), and potentiation by BK between the second (P2) and third (P3) vanilloid pulse (Bottom) in mice
nociceptors. (B) Representative recordings of BK-induced sensitization of capsaicin-evoked neuronal excitability in mice nociceptors preincubated with 20 µM of
DD04107. (C) Mean spike frequency of capsaicin induced AP firing in WT nociceptors. Capsaicin (cps = 500 nM, 15 s) and BK (1 µM, 8 min) were used. DD04107
was preincubated for 1 h at 37◦C. Mean spike frequency was calculated from recordings displayed in (A,B). Data were analyzed as paired values through
comparison of the responses of each electrode in the 30 s time interval upon stimulation Data are expressed as mean ± SEM, n = 4 independent cultures.
Statistical analysis was performed by one-way ANOVA followed by Bonferroni post hoc test. ∗p < 0.05.
FIGURE 7 | BK-induced TRPV1 sensitization in αCGRP−/− nociceptors. (A) Representative traces of capsaicin-evoked APs in primary nociceptor cultures of
DRGs from αCGRP−/− mice upon exposure to buffer (Top) or BK (Bottom) between the second (P2) and third (P3) vanilloid pulse. (B) Mean spike frequency of
capsaicin-evoked AP firing under control and BK treated conditions. Capsaicin (cps = 500 nM, 15 s) and BK (1 µM, 8 min) were used. Mean spike frequency was
calculated from recordings displayed in (A). Data were analyzed as paired values through comparison of the responses of each electrode in the 30 s time interval
upon stimulation. Data are expressed as mean ± SEM. The numbers above the bars represents the total number of electrodes that responded. Number of
independent cultures ≥4. Statistical analysis was performed by one way ANOVA repeated measures with Bonferroni’s post hoc test.
FIGURE 8 | BK-induced TRPV1 sensitization in Tac1−/− nociceptors. (A) Representative traces of capsaicin-evoked APs in primary nociceptor cultures of
DRGs from Tac1−/− mice upon exposure to buffer (Top) or BK (Bottom) between the second (P2) and third (P3) vanilloid pulse. (B) Mean spike frequency of
capsaicin-evoked AP firing under control and BK treated conditions. Capsaicin (cps = 500 nM, 15 s) and BK (1 µM, 8 min) were used. Mean spike frequency was
calculated from recordings displayed in (A). Data were analyzed as paired values through comparison of the responses of each electrode in the 30 s time interval
upon stimulation. Data are expressed as mean ± SEM. The numbers above the bars represents the total number of electrodes that responded. Number of
independent cultures ≥3. Statistical analysis was performed by one-way ANOVA repeated measures with Bonferroni’s post hoc test (∗∗∗p < 0.001).
channels trafficked in αCGRP-loaded LDCVs. And, (iv) BK
sensitization of TRPV1 activity in peptidergic nociceptors is
strictly dependent of αCGRP expression, and it is abrogated
by blockade of Ca2+-activated, SNARE-mediated neuronal
exocytosis with DD04107. Taken together, these findings
indicate that inflammatory sensitization of TRPV1 in peptidergic
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nociceptors is significantly mediated by the mobilization of new
channels to the neuronal surface. Furthermore, they substantiate
that acute peripheral inflammatory sensitization induced by BK
and ATP is largely facilitated by peptidergic nociceptors with
a moderate contribution of the non-peptidergic subpopulation.
In support of this tenet, we also observed that sensitization of
nociceptors with a mixture of BK and ATP was notably attenuated
by blocking neuronal exocytosis with DD04107 (data not
shown). These results corroborate our previously published ATP
experiments, suggesting that both ATP and BK activate Gαq/11
signaling protein and induce TRPV1 exocytosis in peptidergic
nociceptors. Recently, in vivo studies have been performed using
Gαq−/−, Gα11−/−, and Gαq/11−/− knockout mice models to
understand the role of Gαq/11 signaling protein on nociceptor
sensitization induced by algogens. The studies showed that both
ATP and BK induced thermal hyperalgesia was preserved in
Gα11−/− deficient mice, whereas, it was completely abolished
in Gαq−/− and Gαq/11−/− deficient mice. This corroborates
that the major common signaling mechanism involved in
ATP and BK induced nociceptor sensitization is mediated
through Gαq protein and provokes thermal hyperalgesia, where
TRPV1 could play a significant role (Wirotanseng et al.,
2013).
It is notorious the differential sensitizing effect of acute
BK on peptidergic and non-peptidergic nociceptors. In our
experimental conditions, BK mainly excited the peptidergic
nociceptor population. Indeed, the non-peptidergic nociceptors
were rather resistant to BK sensitization, as they were more silent
and required stronger stimulation to trigger APs in agreement
with their more hyperpolarized RMP. A plausible explanation for
this difference may be the differential expression of BK receptor
types in both populations of sensory neurons. In support of
this hypothesis, a BKR1 agonist did not significantly sensitized
our rat nociceptor primary cultures. In contrast, an agonist
of the BKR2 fully mimicked the extent of BK sensitization.
Furthermore, blockade of BKR2 fully inhibited BK-induced
TRPV1 sensitivity while BKR1 antagonists were ineffective.
This observation is in agreement with evidence showing that
BKR2 are constitutively expressed in nociceptors, while BKR1
expression is induced, especially in chronic pain conditions
(Vellani et al., 2004). Accordingly, our results indicate that
acutely instilled BK potentiates TRPV1 activity in peptidergic
nociceptors primarily through the BKR2 by inducing the
exocytosis of αCGRP LDCVs that cargo the thermoTRP channel.
Nonetheless, TRPV1 sensitization also involves modulation
of channel gating as BK potentiation was also abrogated by
PKC blockade (data not shown). Furthermore, our finding
substantiate the tenet that acutely BK sensitization is promoted
by BKR2 signaling, while BKR1 may be involved in chronic
pain. Additional experimentation is required to clearly define
the molecular mechanism involved in acute BK sensitization of
nociceptors.
We previously reported that acute exposure of primary
cultures of nociceptors to BK potentiated TRPV1 responses
by a mechanism that did not involve membrane mobilization
of the thermoTRP channel (Camprubí-Robles et al., 2009),
contrasting with the findings described here. These apparent
contradictory results likely arise from the different experimental
conditions used in both studies. Firstly, the intensity of the
BK stimulus here was 10-fold higher (1.0 µM BK) than
that used by Camprubí-Robles et al. (2009; 0.1 µM BK),
which resulted in a stronger sensitization of the cultured
nociceptors. Secondly, here we have evaluated the effect on
the nociceptor excitability, while in Camprubí-Robles et al.
(2009) capsaicin-evoked Ca2+ fluxes were determined, which
could involve TRPV1 and other Ca2+-permeable channels
activated by membrane depolarization. Thirdly, here we have
differentially evaluated the effect in peptidergic and non-
peptidergic nociceptors, while in Camprubí-Robles et al. (2009)
the response of all nociceptor types was averaged. Independent
of the differences between both studies, here we have shown
that BK strongly potentiates TRPV1 channel activity in rodent
peptidergic nociceptors in culture resulting in robust neuronal
sensitization by partially augmenting the recruitment of new
channels to the plasma membrane through exocytosis of vesicular
channels.
We have also shown that inhibition of Ca2+-dependent,
SNARE-mediated exocytosis of TRPV1 channels is a
pharmacological strategy to reduce the over-excitability
induced by BK. Indeed, peptide DD04107 remarkably reduced
the BK-induced TRPV1 potentiation in peptidergic nociceptors,
which resulted in a reduction of the capsaicin-evoked firing
of APs. As expected the reduction of BK-induced TRPV1
sensitization in nociceptors by DD04107 was not complete,
consistent with reports indicating that the kinin also sensitizes
TRPV1 channels by promoting the PKC phosphorylation of
the channel (Sugiura et al., 2002; Wang et al., 2015), and the
production of endogenous TRPV1 agonists via phospholipase
A2-lipoxygenase pathway (Shin et al., 2002). Nevertheless, our
results lend support to the outstanding in vivo anti-nociceptive
activity of peptide DD04107 (Ponsati et al., 2012), and indicates
that the concomitant modulation of algesic-induced αCGRP
release and membrane mobilization of TRPV1 channels in
peptidergic nociceptors is a promising therapeutic strategy
for pain intervention. In support of this tenet, a recent report
has shown that TNFα induces the co-trafficking of TRPV1
and TRPA1 in LCDVs to the nociceptor membrane and that
botulinum neurotoxins A and C1 inhibited the TNFα elevated
delivery (Meng et al., 2016).
CONCLUSION
Our study reveals that distinct signaling mechanisms are
involved in TRPV1 sensitization induced by BK in peptidergic
and non-peptidergic nociceptors. Furthermore, substantiate the
notion that, similar to ATP, BK induces exocytotic membrane
mobilization of TRPV1 trafficked by αCGRP-containing LDCVs
in peptidergic nociceptors. Furthermore, these findings lend
support to the tenet that algesic recruitment of thermoTRPs
channels and the concurrent release of pro-inflammatory
peptides provides a synergistic mechanism that ensures rapid
modulation of pain peripheral signaling (Devesa et al., 2014;
Meng et al., 2016).
Frontiers in Pharmacology | www.frontiersin.org 10 June 2016 | Volume 7 | Article 178
fphar-07-00178 June 21, 2016 Time: 13:53 # 11
Mathivanan et al. TRPV1 Sensitization by Bradykinin
AUTHOR CONTRIBUTIONS
SM performed research; ID and AF-M designed research;
J-PC contributed new reagents/analytical tools; SM and AF-M
analyzed data; and AF-M wrote the paper.
FUNDING
This work has been supported by grants from the Spanish
Ministerio de Economía y Competitividad (MINECO/FEDER,
EU BFU2012-39092-C02-01 and SAF2015-66275-C2-1-R) to
AF-M and, the Generalitat Valenciana PROMETEO/2014/011
and ISIC/2012/009 to AF-M. SM was a recipient of a GRISOLIA
Fellowship from the Generalitat Valenciana.
ACKNOWLEDGMENT
We are thankful to BCN Peptides for providing the
DD04107, DD04107RDM and non-palmitoylated DD04107
compounds.
REFERENCES
Baker, M. D., and Bostock, H. (1997). Low-threshold, persistent sodium current in
rat large dorsal root ganglion neurons in culture. J. Neurophysiol. 77, 1503–1513.
Bonnington, J. K., and McNaughton, P. A. (2003). Signalling pathways involved
in the sensitisation of mouse nociceptive neurones by nerve growth factor.
J. Physiol. 551, 433–446. doi: 10.1113/jphysiol.2003.039990
Camprubí-Robles, M., Planells-Cases, R., and Ferrer-Montiel, A. (2009).
Differential contribution of SNARE-dependent exocytosis to inflammatory
potentiation of TRPV1 in nociceptors. FASEB J. 23, 3722–3733. doi:
10.1096/fj.09-134346
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., and
Julius, D. (1997) The capsaicin receptor: a heat-activated ion channel in the pain
pathway. Nature 389, 816–824. doi: 10.1038/39807
Cavanaugh, D. J., Chesler, A. T., Braz, J. M., Shah, N. M., Julius, D., and
Basbaum, A. I. (2011). Restriction of transient receptor potential vanilloid-1
to the peptidergic subset of primary afferent neurons follows its developmental
downregulation in nonpeptidergic neurons. J. Neurosci. 31, 10119–10127. doi:
10.1523/JNEUROSCI.1299-11.2011
Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and McNaughton, P. A.
(1999). Specific involvement of PKC-epsilon in sensitization of the neuronal
response to painful heat. Neuron 23, 617–624. doi: 10.1016/S0896-6273(00)
80813-2
Cesare, P., and McNaughton, P. (1996). A novel heat-activated current in
nociceptive neurons and its sensitization by bradykinin. Proc. Natl. Acad. Sci.
U.S.A. 93, 15435–15439. doi: 10.1073/pnas.93.26.15435
Chu, C. J., Huang, S. M., De Petrocellis, L., Bisogno, T., Ewing, S. A., Miller,
J. D., et al. (2003). N-oleoyldopamine, a novel endogenous capsaicin-like
lipid that produces hyperalgesia. J. Biol. Chem. 278, 13633–13639. doi:
10.1074/jbc.M211231200
Cui, M., Khanijou, S., Rubino, J., and Aoki, K. R. (2004). Subcutaneous
administration of botulinum toxin A reduces formalin-induced pain. Pain 107,
125–133. doi: 10.1016/j.pain.2003.10.008
Davis, A. J., and Perkins, M. N. (1994). Induction of B1 receptors in vivo
in a model of persistent inflammatory mechanical hyperalgesia in the rat.
Neuropharmacology 33, 127–133. doi: 10.1016/0028-3908(94)90107-4
Devesa, I., Ferrandiz-Huertas, C., Mathivanan, S., Wolf, C., Lujan, R., Changeux,
J. P., et al. (2014). alphaCGRP is essential for algesic exocytotic mobilization of
TRPV1 channels in peptidergic nociceptors. Proc. Natl. Acad. Sci. U.S.A. 111,
18345–18350. doi: 10.1073/pnas.1420252111
Dray, A., and Perkins, M. (1993). Bradykinin and inflammatory pain. Trends
Neurosci. 16, 99–104. doi: 10.1016/0166-2236(93)90133-7
Gold, M. S., and Traub, R. J. (2004). Cutaneous and colonic rat DRG
neurons differ with respect to both baseline and PGE2-induced changes
in passive and active electrophysiological properties. J. Neurophysiol. 91,
2524–2531. doi: 10.1152/jn.00866.2003
Huang, J., Zhang, X., and McNaughton, P. A. (2006). Inflammatory pain: the
cellular basis of heat hyperalgesia. Curr. Neuropharmacol. 4, 197–206. doi:
10.2174/157015906778019554
Huang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F.,
et al. (2002). An endogenous capsaicin-like substance with high potency at
recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U.S.A.
99, 8400–8405. doi: 10.1073/pnas.122196999
Kim, D. W., Lee, S. K., and Ahnn, J. (2015). Botulinum toxin as a pain
killer: players and actions in antinociception. Toxins 7, 2435–2453. doi:
10.3390/toxins7072435
Lee, Y. J., Zachrisson, O., Tonge, D. A., and McNaughton, P. A. (2002).
Upregulation of bradykinin B2 receptor expression by neurotrophic factors and
nerve injury in mouse sensory neurons. Mol. Cell. Neurosci. 19, 186–200. doi:
10.1006/mcne.2001.1073
Ma, Q. P. (2001). The expression of bradykinin B(1) receptors on primary sensory
neurones that give rise to small caliber sciatic nerve fibres in rats. Neuroscience
107, 665–673. doi: 10.1016/S0306-4522(01)00387-6
Mamet, J., Baron, A., Lazdunski, M., and Voilley, N. (2002). Proinflammatory
mediators, stimulators of sensory neuron excitability via the expression of
acid-sensing ion channels. J. Neurosci. 22, 10662–10670.
Meng, J., Wang, J., Lawrence, G., and Dolly, J. O. (2007). Synaptobrevin I mediates
exocytosis of CGRP from sensory neurons and inhibition by botulinum
toxins reflects their anti-nociceptive potential. J. Cell Sci. 120, 2864–2874. doi:
10.1242/jcs.012211
Meng, J., Wang, J., Steinhoff, M., and Dolly, J. O. (2016). TNFalpha induces
co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the
plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion. Sci. Rep.
6:21226. doi: 10.1038/srep21226
Mitchell, K., Bates, B. D., Keller, J. M., Lopez, M., Scholl, L., Navarro, J., et al. (2010).
Ablation of rat TRPV1-expressing Adelta/C-fibers with resiniferatoxin: analysis
of withdrawal behaviors, recovery of function and molecular correlates. Mol.
Pain 6:94. doi: 10.1186/1744-8069-6-94
Mizumura, K., Sugiura, T., Katanosaka, K., Banik, R. K., and Kozaki, Y. (2009).
Excitation and sensitization of nociceptors by bradykinin: what do we know?
Exp. Brain Res. 196, 53–65. doi: 10.1007/s00221-009-1814-5
Morenilla-Palao, C., Planells-Cases, R., Garcia-Sanz, N., and Ferrer-Montiel, A.
(2004). Regulated exocytosis contributes to protein kinase C potentiation
of vanilloid receptor activity. J. Biol. Chem. 279, 25665–25672. doi:
10.1074/jbc.M311515200
Patwardhan, A. M., Berg, K. A., Akopain, A. N., Jeske, N. A., Gamper, N.,
Clarke, W. P., et al. (2005). Bradykinin-induced functional competence and
trafficking of the delta-opioid receptor in trigeminal nociceptors. J. Neurosci.
25, 8825–8832. doi: 10.1523/JNEUROSCI.0160-05.2005
Petho, G., and Reeh, P. W. (2012). Sensory and signaling mechanisms of
bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral
nociceptors. Physiol. Rev. 92, 1699–1775. doi: 10.1152/physrev.00048.2010
Pettinger, L., Gigout, S., Linley, J. E., and Gamper, N. (2013). Bradykinin controls
pool size of sensory neurons expressing functional delta-opioid receptors.
J. Neurosci. 33, 10762–10771. doi: 10.1523/JNEUROSCI.0123-13.2013
Planells-Cases, R., Garcia-Sanz, N., Morenilla-Palao, C., and Ferrer-Montiel, A.
(2005). Functional aspects and mechanisms of TRPV1 involvement in
neurogenic inflammation that leads to thermal hyperalgesia. Pflugers Arch. 451,
151–159. doi: 10.1007/s00424-005-1423-5
Ponsati, B., Carreno, C., Curto-Reyes, V., Valenzuela, B., Duart, M. J., Van
den Nest, W., et al. (2012). An inhibitor of neuronal exocytosis (DD04107)
displays long-lasting in vivo activity against chronic inflammatory and
neuropathic pain. J. Pharmacol. Exp. Ther. 341, 634–645. doi: 10.1124/jpet.111.
190678
Premkumar, L. S., and Ahern, G. P. (2000). Induction of vanilloid receptor channel
activity by protein kinase C. Nature 408, 985–990. doi: 10.1038/35050121
Frontiers in Pharmacology | www.frontiersin.org 11 June 2016 | Volume 7 | Article 178
fphar-07-00178 June 21, 2016 Time: 13:53 # 12
Mathivanan et al. TRPV1 Sensitization by Bradykinin
Raidoo, D. M., and Bhoola, K. D. (1998). Pathophysiology of the kallikrein-
kinin system in mammalian nervous tissue. Pharmacol. Ther. 79, 105–127. doi:
10.1016/S0163-7258(98)00011-4
Salmon, A. M., Damaj, I., Sekine, S., Picciotto, M. R., Marubio, L., and Changeux,
J. P. (1999). Modulation of morphine analgesia in alphaCGRP mutant mice.
Neuroreport 10, 849–854. doi: 10.1097/00001756-199903170-00033
Seabrook, G. R., Bowery, B. J., Heavens, R., Brown, N., Ford, H., Sirinathsinghi,
D. J., et al. (1997). Expression of B1 and B2 bradykinin receptor mRNA and
their functional roles in sympathetic ganglia and sensory dorsal root ganglia
neurones from wild-type and B2 receptor knockout mice. Neuropharmacology
36, 1009–1017. doi: 10.1016/S0028-3908(97)00065-8
Shimizu, T., Shibata, M., Toriumi, H., Iwashita, T., Funakubo, M., Sato, H., et al.
(2012). Reduction of TRPV1 expression in the trigeminal system by botulinum
neurotoxin type-A. Neurobiol. Dis. 48, 367–378. doi: 10.1016/j.nbd.2012.
07.010
Shin, J., Cho, H., Hwang, S. W., Jung, J., Shin, C. Y., Lee, S. Y., et al.
(2002). Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory
hyperalgesia. Proc. Natl. Acad. Sci. U.S.A. 99, 10150–10155. doi: 10.1073/
pnas.152002699
Sidaway, P. (2015). Pain: BoNT-A reduces pain in patients with treatment
refractory IC/BPS. Nat. Rev. Urol. 12:300. doi: 10.1038/nrurol.2015.101
Siemens, J., Zhou, S., Piskorowski, R., Nikai, T., Lumpkin, E. A., Basbaum,
A. I., et al. (2006). Spider toxins activate the capsaicin receptor to produce
inflammatory pain. Nature 444, 208–212. doi: 10.1038/nature05285
Srinivasan, R., Wolfe, D., Goss, J., Watkins, S., de Groat, W. C., Sculptoreanu, A.,
et al. (2008). Protein kinase C epsilon contributes to basal and sensitizing
responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur. J.
Neurosci. 28, 1241–1254. doi: 10.1111/j.1460-9568.2008.06438.x
Stucky, C. L., and Lewin, G. R. (1999). Isolectin B(4)-positive and -negative
nociceptors are functionally distinct. J. Neurosci. 19, 6497–6505.
Sugiura, T., Tominaga, M., Katsuya, H., and Mizumura, K. (2002). Bradykinin
lowers the threshold temperature for heat activation of vanilloid receptor 1.
J. Neurophysiol. 88, 544–548.
Supowit, S. C., Zhao, H., Katki, K. A., Gupta, P., and Dipette, D. J. (2011).
Bradykinin and prostaglandin E(1) regulate calcitonin gene-related peptide
expression in cultured rat sensory neurons. Regul. Pept. 167, 105–111. doi:
10.1016/j.regpep.2010.12.006
Vellani, V., Zachrisson, O., and McNaughton, P. A. (2004). Functional
bradykinin B1 receptors are expressed in nociceptive neurones and are
upregulated by the neurotrophin GDNF. J. Physiol. 560, 391–401. doi:
10.1113/jphysiol.2004.067462
Walker, K., Perkins, M., and Dray, A. (1995). Kinins and kinin receptors in the
nervous system. Neurochem. Int. 26, 1–16; discussion 17–26. doi: 10.1016/0197-
0186(94)00114-A
Wang, S., Joseph, J., Ro, J. Y., and Chung, M. K. (2015). Modality-
specific mechanisms of protein kinase C-induced hypersensitivity of TRPV1:
S800 is a polymodal sensitization site. Pain 156, 931–941. doi: 10.1097/
j.pain.0000000000000134
Wirotanseng, L. N., Kuner, R., and Tappe-Theodor, A. (2013). Gq rather than
G11 preferentially mediates nociceptor sensitization. Mol. Pain 9:54. doi:
10.1186/1744-8069-9-54
Wotherspoon, G., and Winter, J. (2000). Bradykinin B1 receptor is constitutively
expressed in the rat sensory nervous system. Neurosci. Lett. 294,
175–178. doi: 10.1016/S0304-3940(00)01561-5
Yu, L., Yang, F., Luo, H., Liu, F. Y., Han, J. S., Xing, G. G., et al. (2008). The role
of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic
inflammatory nociception induced by complete Freund’s adjuvant. Mol. Pain
4:61. doi: 10.1186/1744-8069-4-61
Zhang, X., Li, L., and McNaughton, P. A. (2008). Proinflammatory mediators
modulate the heat-activated ion channel TRPV1 via the scaffolding protein
AKAP79/150. Neuron 59, 450–461. doi: 10.1016/j.neuron.2008.05.015
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M.,
Di Marzo, V., et al. (1999). Vanilloid receptors on sensory nerves mediate
the vasodilator action of anandamide. Nature 400, 452–457. doi: 10.1038/
22761
Conflict of Interest Statement: AF-M is an inventor of a patent application
protecting the algesic activity of DD04107. WO 2010/009892 A2. The remaining
authors declare that the research was conducted in the absence of any commercial
or financial relationships that could be construed as a potential conflict of interest.
The reviewer JB and handling Editor declared their shared affiliation, and the
handling Editor states that the process nevertheless met the standards of a fair and
objective review.
Copyright © 2016 Mathivanan, Devesa, Changeux and Ferrer-Montiel. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 12 June 2016 | Volume 7 | Article 178
